Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

Complete Title: Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody
Trial Phase: N/A
Investigator: Sarah Lee

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Checklist icon

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.

N/A
Sarah Lee
RG1123502
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody